19:01 , May 8, 2017 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds Three cyclic peptide-based inhibitors of KDM4A , KDM4B and KDM4C could be useful for probing the role of the enzymes in cancer. Screening of a library of thioether-based macrocycles in vitro identified...
08:00 , Nov 15, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Jumonji domain containing 2C (JMJD2C; KDM4C) Cell culture, mouse and patient sample studies suggest inhibiting JMJD2C could help treat breast cancer. In a...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Chemistry

This week in techniques Approach Summary Licensing status Publication and contact information Chemistry Small molecule inhibitor of jumonji C domain-containing histone demethylases (JHDMs) A small molecule inhibitor of JHDMs could help validate disease targets and...
07:00 , Jul 29, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Jumonji domain containing 2C (JMJD2C; KDM4C) In vitro and SAR studies identified inhibitors of JMJD2C that could be used in combination with lysine-specific histone...
08:00 , Dec 14, 2009 |  BioCentury  |  Emerging Company Profile

IkerChem: Binding site rationale

IkerChem S.L. is using computational drug design to develop molecules that cover the entire active binding site of their targets. The company believes the approach can yield a larger number of more potent hits in...